PharmedOut leaders are spreading misinformation when they say Medicare’s coverage requirement for early Alzheimer’s patients to access FDA-approved drugs puts “no burden on the patient” (“The danger to patients of pharma-funded surveys,” Dec. 2).
In fact, Medicare mandates that, for patients to have coverage for early Alzheimer’s therapies, they must participate in a clinical study. The study data is collected in a registry, but the registry itself is not the study. If a patient does not want to participate in such a study to get the therapy covered, they would have to either pay out of their own pocket or relinquish access.
The authors neglect to mention that Medicare’s restrictive policy has only ever been applied to these early Alzheimer’s therapies. No other FDA-approved drug for any disease has these Medicare coverage requirements, so we wanted to know how likely voters felt about that. It turns out, they overwhelmingly think it’s unfair, regardless of their political party. We can only guess that the authors didn’t like those results, but we’re not sure why.
Sue Peschin, MHS
Ms. Peschin is President and
CEO of the Alliance For Aging Research.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.